| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 |
|
Medicine details |
|
| Medicine name | tixagevimab/cilgavimab (Evusheld®) |
| Formulation | solution for injection |
| Reference number | 5277 |
| Indication | Treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19 |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Respiratory system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 22/03/2023 |
| NICE guidance | TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 |